NCT06216093View on ClinicalTrials.gov

Phase I, First-In Human Study to Evaluate Safety and Tolerability of EuRSV in Healthy Adults Aged Between 19 Years and 80 Years

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

May 8, 2024

Primary Completion Date

July 31, 2025

Study Completion Date

September 30, 2025

Conditions
Respiratory Syncytial Virus InfectionsRespiratory Syncytial Virus (RSV)
Interventions
BIOLOGICAL

EuRSV

Healthy adults received 0.5mL single intramuscular dose on Day 0 and Day 28.

OTHER

Placebo Comparator

Healthy adults received 0.5mL single intramuscular dose on Day 0 and Day 28.

Trial Locations (1)

Unknown

Univsersity Hospital, Seoul

Sponsors
All Listed Sponsors
lead

EuBiologics Co.,Ltd

INDUSTRY